CD274 and non-small cell lung carcinoma: In another clinical trial, the combination of tiragolumab + atezolizumab (anti-PD-L1) compared with the combination of placebo + atezolizumab for the treatment of NSCLC also achieved an increase in ORR (37.3% and 20.6%, respectively) and median disease-free survival (5.6 and 3.9 months, respectively) [135].